Important data reveals are expected from Madrigal, Arrowhead and Ascendis, with details from Biogen and Eisai due at a conference.
But progress – or lack thereof – with lenacapavir is a more immediate concern.
Key upcoming clinical results approach in the third quarter for lecanemab, high-dose Eylea and Zimura.
Despite the often dismal mood over the weekend, the Asco conference provided rich pickings for some biotech investors.
Roche’s SCLC study is an unmitigated disaster, but investors holding out for success in NSCLC are thrown a crumb of comfort.
Unveiled abstracts from Asco lift the stock of several biotechs, which will now be under pressure not to disappoint at the conference next week.
Following the Pfizer-Biohaven blueprint, could other licensing deals turn into buyouts?